Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
Henderson et al reported that allergen induced airway
2019-10-15
Henderson et al. [20] reported that allergen-induced airway remodeling was blocked by the CysLT1 receptor antagonist montelukast. The development of epithelial thickening and mucus accumulation at relatively small glatiramer acetate was also suppressed by montelukast. The CysLT2 receptor antagonist
-
Picrotoxin The early serologic response of infants to infect
2019-10-15
The early serologic response of infants to infection with HIV-1 is obscured by the presence of transplacentally acquired maternal HIV antibody. However, the HIV Picrotoxin produced in vitro by peripheral blood from infants has been studied (Pollack et al., 1993) and it has been shown that neonatal i
-
br Acknowledgements The authors thank Drs
2019-10-15
Acknowledgements The authors thank Drs. C. Klein, I. Canisso and A. Claes with assistance in obtaining tissues. Supported by the Albert G. Clay Endowment, University of Kentucky. Introduction Neoplastic cells often develop drug resistance during tumor progression or cancer treatment (Turner a
-
br Conclusion To our knowledge this study is the first
2019-10-14
Conclusion To our knowledge, this study is the first to give evidence that the ETA selective antagonist BQ-123 reverses the cisplatin-induced ARF mainly via restoring SOD activity, in addition to other antioxidant parameters, NO, TNF-α and caspase-3 levels. And that this protective effect require
-
Protein ubiquitination occurs at the lysine residues and is
2019-10-14
Protein ubiquitination occurs at the lysine residues, and is mediated by the sequential reactions of ubiquitin-activating enzyme (E1), conjugating enzyme (E2), and ligase (E3). The first step in this process comprises the ATP-dependent activation of ubiquitin by E1 to form a ubiquitin–E1 conjugate.
-
br Materials and methods BAECs CAB Toyobo
2019-10-14
Materials and methods BAECs (CAB30405, Toyobo Life Science, Osaka, Japan) were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (04-001-1A-US, Biological Industries, Kibbutz Beit Haemek, Israel) and 1% antibiotic-antifungal agent containing 10,000-μg/mL penici
-
br Acknowledgments This work was supported by a grant
2019-10-14
Acknowledgments This work was supported by a grant from the National Center for GM Crops (PJ008152) of the Next Generation BioGreen 21 Program funded by the Rural Development Administration, Republic of Korea, to W.T.K. Introduction Ubiquitin (Ub) has been considered as one of the most import
-
More unusual modifications also regulate DUBs Recent reports
2019-10-14
More unusual modifications also regulate DUBs. Recent reports have illustrated how reactive oxygen species (ROS) can regulate DUB activity 87, 88, 89, 90. ROS can serve as potent signaling molecules by reacting with active site cysteines of tyrosine phosphatases and some cysteine peptidases to form
-
Introduction Collagen deposition is a common feature
2019-10-14
Introduction Collagen deposition is a common feature found in cancerous tissues and fibrotic organs/lesions. It is now well accepted that collagen deposition is not just a consequence of disease, but that it can also trigger a vicious cycle. Both chemical and physical signals elicited from collagen
-
The synthesis of the required substrates is shown in
2019-10-14
The synthesis of the required substrates is shown in (see for experimental details). Treatment of heterocycle with hdac inhibitors under basic conditions afforded a mixture of the mono-substituted product (22%) and the di-substituted compound (38%) which were separated by column chromatography. Comp
-
br ET Antagonist for the Future Macitentan and Atresentan Ma
2019-10-14
ET Antagonist for the Future: Macitentan and Atresentan Macitentan is an insurmountable antagonist, resulting from structure-activity studies to improve the efficacy and tolerability of bosentan, and gained approval in the United States in 2013 for the treatment of PAH. Actelion describes the com
-
Results from experiments in model systems
2019-10-14
Results from experiments in model systems have suggested that the DPRs translated from the HRE of C9ORF72 are toxic and play a role in disease pathogenesis (reviewed in Taylor et al. (2016)). Although the DPRs are present in neurons and glia in various regions of the central nervous system (CNS) ear
-
br Introduction The protein Epidermal Growth
2019-10-14
Introduction The protein Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) play important role in non small-cell lung carcinoma (NSCLC) and vital therapeutic progress withinin the treatment of this ailment has revamped the past ten years through the exploitation of this insight (Mok et a
-
Once sufficient single stranded DNA ssDNA has been exposed
2019-10-14
Once sufficient single-stranded DNA (ssDNA) has been exposed at origins, synthesis of leading and lagging strands is initiated by the DNA polymerase α-primase complex (Pol α). Lagging-strand synthesis requires repeated cycles of Pol α-dependent priming and subsequent primer extension by Pol δ. Pol α
-
br Conclusion br Conflict of interest br Author contribution
2019-10-14
Conclusion Conflict of interest Author contributions Acknowledgements Piyamas Kanokwongnuwut was supported by the Development and Promotion of Science and Technology Talent Project (DPST), Royal Thai Government Scholarship. Funding for the work was provided by the Attorney General’s Depa
14932 records 943/996 page Previous Next First page 上5页 941942943944945 下5页 Last page